Back to Rankings

VRAX

Virax Biolabs GroupF
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart
Documents
1
Stored
Transcripts
0
Recent loaded
Latest report
2025-07-04
Investor release

Document history

Earnings documents stored for VRAX.

1 shown
Investor releaseQuarter not tagged2025-07-04

Virax Biolabs Group Full Year 2025 Earnings: Misses Expectations

Simply Wall St.

Net loss: US$6.06m (loss narrowed by 10.0% from FY 2024). US$1.63 loss per share (improved from US$3.36 loss in FY 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 75%. Earnings per share (EPS) also missed analyst estimates by 9.5%. The company's shares are up 10% from a week ago. Before you take the next step you should know about the 6 warning signs for Virax Biolabs Group (5 are a bit unpleasant!) that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

As of 2026-05-18 • Updated weeklySource: Earnings sourceIngestion runbook